February 19. 2019 in Paris. Martin Koch, COO of Inotrem, participates to “Market Access and Biotechnologies”, a panel discussion organized by France Biotech, France’s main non-profit organization which brings together the country’s leading innovative health companies and their expert partners. www.france-biotech.fr
January 23.-26. 2019 in Paris. Reanimation 2019 is the Annual congress organized by the French Intensive Care Society (www.srlf.org). Dr. Bruno François, Coordinating Physician at the CHU of Limoges, will present the MOT-C-201 Clinical Trial Results regarding safety and tolerability of nangibotide (LR12) in patients with septic shock. www.reanimation-lecongres.com
The study demonstrated the safety and tolerability of its lead compound in patients suffering from septic shock Paris, October 1st. 2018. Inotrem S.A., a biotechnology focused on the modulation of the TREM pathway for the management of inflammatory syndromes, announced positive results for its Phase IIa study that demonstrated the
October 1-3, 2018 in Bangkok, Thailand The International Sepsis Forum (ISF) is an international collaboration to reduce the global burden of sepsis guided by prominent academics from around the world. Sepsis 2018 will be held as a joint meeting with the Thai Society of Critical Sepsis 2018 Medicine. http://internationalsepsisforum.com/
October 3-4. 2018 in Basel, Switzerland The 18th Annual Biotech in Europe Forum is recognized as the leading international stage for those interested in investing and partnering in the biotech and life science industry. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading
October 23. 2018 in Tokyo, Japan Sofinnova Partners is an independent venture capital firm based in Paris. Over the past 40 years, the firm has financed and accompanied almost 500 companies. http://www.sofinnova.fr/en/
November 5-7. 2018 in Copenhagen, Denmark The 23rd annual international partnering conference BIO-Europe offers world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business. https://ebdgroup.knect365.com/bioeurope/
Paris, January 18th . 2018. Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes such as septic shock, has appointed Martin Koch as Chief Operating Officer (COO). Martin Koch comes to Inotrem with more than 25 years of experience in the healthcare industry. Prior to joining
Paris, November 15, 2017. Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes, today announced that the European Medicines Agency (EMA) has granted access to its PRIority MEdicines (PRIME) scheme for its lead product MOTREMTM in the field of septic shock.
Paris, November 10, 2017. Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes, such as septic shock, today announced a R&D collaboration agreement with Roche Diagnostics to develop a companion diagnostic test using a soluble plasma circulating protein (sTREM-1) developed by Inotrem and the Roche proprietary
Paris, September 13 th. 2017. Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes, such as septic shock, announced today that preclinical results show a direct and strong protective effect of its lead product candidate LR12 on vascular function during experimental septic shock. The firm was
Paris, France, September 13, 2016 – Inotrem SA, a biotechnology company specialized in the control of acute inflammatory syndromes, such as septic shock, announced today the successful completion of the first clinical trial of Motrem in healthy volunteers. The principal objective of this first in-man phase I clinical trial, conducted
Paris and Nancy, France, March 13 2014 – Inotrem S.A., a French biotech company specialized in the control of immune reaction in acute inflammatory diseases, announced today the completion of its Series A financing round. With a total of €18 million, this round is the largest Series A round in
INOTREM S.A | 54 rue de Ponthieu 75008 PARIS
Inotrem 2018 – Legal notices
INOTREM S.A | 114 rue la Boétie 75008 PARIS
Inotrem 2018 – Legal notices